- Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor
- A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
- RZ358 Treatment for Congenital Hyperinsulinism
- An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism
All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.